Sircar S, Cai F, Begin M E, Weber J M
Département de Microbiologie, Faculté de Médecine, Université de Sherbrooke, Québec, Canada.
Anticancer Res. 1990 Nov-Dec;10(6):1783-6.
A series of genetically related cell lines that express mdr genes but differ in their ability to form tumors has been challenged with gamma-linolenate and eicosapentaenoate to verify if the sensitivity of tumorigenic mdr cells to cytotoxic PUFAs differs from the sensitivity of non-tumorigenic mdr cells. The tumorigenic mdr cell lines were derived by transformation of their parental non-tumorigenic mdr cell line with myc and ras oncogenes. Four ras and five myc transformed cell lines were used for the estimation of clonal variability. The data as based on colony forming assays, showed that six out of nine of the tumorigenic mdr cell lines were more sensitive than the non-tumorigenic mdr cells. These results suggest that a tumorigenic phenotype renders mdr cells more sensitive to PUFAs and that PUFA supplementation either alone or in conjunction with existing forms of cancer therapy may have significant clinical implications.
一系列表达多药耐药(mdr)基因但形成肿瘤能力不同的基因相关细胞系,已用γ-亚麻酸和二十碳五烯酸进行了挑战,以验证致瘤性mdr细胞对细胞毒性多不饱和脂肪酸(PUFAs)的敏感性是否不同于非致瘤性mdr细胞。致瘤性mdr细胞系是通过用myc和ras癌基因转化其亲代非致瘤性mdr细胞系而获得的。四个ras和五个myc转化细胞系用于评估克隆变异性。基于集落形成试验的数据表明,九个致瘤性mdr细胞系中有六个比非致瘤性mdr细胞更敏感。这些结果表明,致瘤表型使mdr细胞对PUFAs更敏感,并且单独或与现有癌症治疗形式联合补充PUFA可能具有重大的临床意义。